Form 4: Arcutis Biotherapeutics Director and 10% Owner Patrick Heron Reports Significant Equity Grants

Patrick J. Heron, a Director and 10% owner of Arcutis Biotherapeutics, Inc., reported the acquisition of Restricted Stock Units and stock options as part of his compensation.

Summary

• Patrick J. Heron, a Director and 10% Owner of Arcutis Biotherapeutics, Inc. (ARQT), filed a Form 4 detailing recent equity transactions.
• Mr. Heron acquired 7,609 Restricted Stock Units (RSUs) at a price of $0, granted in connection with his service as a non-employee director.
• These RSUs are set to vest on the earlier of June 12, 2025, or immediately before the next annual meeting of stockholders, subject to continued service.
• The settlement of these RSUs has been deferred by Mr. Heron, as per an RSU Deferral Election Form adopted on October 23, 2024.
• Additionally, Mr. Heron acquired 20,568 stock options with an exercise price of $13.50 per share.
• These stock options also vest 100% on the earlier of June 12, 2025, or immediately before the next annual meeting of stockholders, subject to continued service, and have an expiration date of June 12, 2035.
• Following these transactions, Mr. Heron directly beneficially owns 26,435 shares of common stock and 20,568 stock options.
• Indirectly, Mr. Heron beneficially owns 24,802 shares through Frazier Life Sciences X, L.P., 8,785,284 shares through Frazier Life Sciences VIII, L.P., 7 shares through FHM Life Sciences VIII, L.L.C., and 23,688 shares through The Heron Living Trust 11/30/2004, disclaiming beneficial ownership except for his pecuniary interest.

Sentiment

Score: 6

Explanation: The filing is a routine SEC Form 4 reporting equity compensation for a director, which is a standard practice and generally viewed neutrally or slightly positively as it aligns insider interests with shareholders. It does not contain information that would significantly alter the company's outlook.

Positives

• The acquisition of Restricted Stock Units and stock options by a director and 10% owner aligns management's interests with those of shareholders, as their compensation is tied to the company's equity performance.

Risks

• The reporting person disclaims beneficial ownership of securities held indirectly through Frazier Life Sciences X, L.P., Frazier Life Sciences VIII, L.P., FHM Life Sciences VIII, L.L.C., and The Heron Living Trust 11/30/2004, except to the extent of his pecuniary interest, which is a standard disclaimer but highlights complex ownership structures.

Future Outlook

The document indicates that the granted Restricted Stock Units and stock options will vest on the earlier of June 12, 2025, or immediately before the next annual meeting of stockholders, subject to continued service.

Industry Context

The granting of equity compensation, such as Restricted Stock Units and stock options, to non-employee directors is a common practice across the biotechnology and broader public company landscape. This aligns the interests of the director with the long-term performance of the company, a standard governance practice.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership through Frazier Life Sciences X, L.P., Frazier Life Sciences VIII, L.P., and FHM Life Sciences VIII, L.L.C., where the reporting person is one of two managing members, with beneficial ownership disclaimed except for pecuniary interest.
• Indirect beneficial ownership through The Heron Living Trust 11/30/2004, where the reporting person is the co-trustee with voting and investment power, with beneficial ownership disclaimed except for pecuniary interest.

Stakeholder Impact

• Shareholders: The equity grants to a director align his financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• Vesting of 7,609 Restricted Stock Units on the earlier of June 12, 2025, or immediately before the next annual meeting of stockholders.
• Vesting of 20,568 stock options on the earlier of June 12, 2025, or immediately before the next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Arcutis Biotherapeutics, ARQT, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership, Biotechnology